163 related articles for article (PubMed ID: 23036472)
21. Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers.
Sliepen K; Medina-Ramírez M; Yasmeen A; Moore JP; Klasse PJ; Sanders RW
Virology; 2015 Dec; 486():116-20. PubMed ID: 26433050
[TBL] [Abstract][Full Text] [Related]
22. Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41.
Zhang MY; Yuan T; Li J; Rosa Borges A; Watkins JD; Guenaga J; Yang Z; Wang Y; Wilson R; Li Y; Polonis VR; Pincus SH; Ruprecht RM; Dimitrov DS
PLoS One; 2012; 7(9):e44241. PubMed ID: 22970187
[TBL] [Abstract][Full Text] [Related]
23. Germline-targeting immunogens.
Stamatatos L; Pancera M; McGuire AT
Immunol Rev; 2017 Jan; 275(1):203-216. PubMed ID: 28133796
[TBL] [Abstract][Full Text] [Related]
24. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
25. Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies.
Williams WB; Wiehe K; Saunders KO; Haynes BF
J Int AIDS Soc; 2021 Nov; 24 Suppl 7(Suppl 7):e25831. PubMed ID: 34806332
[TBL] [Abstract][Full Text] [Related]
26. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies.
McGuire AT; Hoot S; Dreyer AM; Lippy A; Stuart A; Cohen KW; Jardine J; Menis S; Scheid JF; West AP; Schief WR; Stamatatos L
J Exp Med; 2013 Apr; 210(4):655-63. PubMed ID: 23530120
[TBL] [Abstract][Full Text] [Related]
27. HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
LaBranche CC; McGuire AT; Gray MD; Behrens S; Kwong PDK; Chen X; Zhou T; Sattentau QJ; Peacock J; Eaton A; Greene K; Gao H; Tang H; Perez LG; Chen X; Saunders KO; Kwong PD; Mascola JR; Haynes BF; Stamatatos L; Montefiori DC
PLoS Pathog; 2018 Nov; 14(11):e1007431. PubMed ID: 30395637
[TBL] [Abstract][Full Text] [Related]
28. Antibodies from Rabbits Immunized with HIV-1 Clade B SOSIP Trimers Can Neutralize Multiple Clade B Viruses by Destabilizing the Envelope Glycoprotein.
van Haaren MM; McCoy LE; Torres JL; Lee W; Cottrell CA; Copps JL; van der Woude P; Yasmeen A; de Taeye SW; Torrents de la Peña A; Moore JP; Burton DR; Klasse PJ; Ward AB; Sanders RW; van Gils MJ
J Virol; 2021 Aug; 95(17):e0009421. PubMed ID: 34076487
[TBL] [Abstract][Full Text] [Related]
29. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
[TBL] [Abstract][Full Text] [Related]
30. Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.
Crooks ET; Grimley SL; Cully M; Osawa K; Dekkers G; Saunders K; Rämisch S; Menis S; Schief WR; Doria-Rose N; Haynes B; Murrell B; Cale EM; Pegu A; Mascola JR; Vidarsson G; Binley JM
PLoS Pathog; 2018 May; 14(5):e1007024. PubMed ID: 29718999
[TBL] [Abstract][Full Text] [Related]
31. Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope.
Doores KJ; Kong L; Krumm SA; Le KM; Sok D; Laserson U; Garces F; Poignard P; Wilson IA; Burton DR
J Virol; 2015 Jan; 89(2):1105-18. PubMed ID: 25378488
[TBL] [Abstract][Full Text] [Related]
32. Membrane Env Liposomes Facilitate Immunization with Multivalent Full-Length HIV Spikes.
Leaman DP; Stano A; Chen Y; Zhang L; Zwick MB
J Virol; 2021 Jun; 95(13):e0000521. PubMed ID: 33883221
[TBL] [Abstract][Full Text] [Related]
33. A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies.
Fetzer I; Davis-Gardner ME; Gardner MR; Alfant B; Weber JA; Prasad NR; Zhou AS; Farzan M
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541842
[TBL] [Abstract][Full Text] [Related]
34. Functional interrogation and mining of natively paired human V
Wang B; DeKosky BJ; Timm MR; Lee J; Normandin E; Misasi J; Kong R; McDaniel JR; Delidakis G; Leigh KE; Niezold T; Choi CW; Viox EG; Fahad A; Cagigi A; Ploquin A; Leung K; Yang ES; Kong WP; Voss WN; Schmidt AG; Moody MA; Ambrozak DR; Henry AR; Laboune F; Ledgerwood JE; Graham BS; Connors M; Douek DC; Sullivan NJ; Ellington AD; Mascola JR; Georgiou G
Nat Biotechnol; 2018 Feb; 36(2):152-155. PubMed ID: 29309060
[TBL] [Abstract][Full Text] [Related]
35. Antigenicity and immunogenicity of HIV-1 gp140 with different combinations of glycan mutation and V1/V2 region or V3 crown deletion.
Fu M; Hu K; Hu H; Ni F; Du T; Shattock RJ; Hu Q
Vaccine; 2019 Dec; 37(51):7501-7508. PubMed ID: 31564450
[TBL] [Abstract][Full Text] [Related]
36. VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA.
Jia M; Liberatore RA; Guo Y; Chan KW; Pan R; Lu H; Waltari E; Mittler E; Chandran K; Finzi A; Kaufmann DE; Seaman MS; Ho DD; Shapiro L; Sheng Z; Kong XP; Bieniasz PD; Wu X
Cell Host Microbe; 2020 Jun; 27(6):963-975.e5. PubMed ID: 32315598
[TBL] [Abstract][Full Text] [Related]
37. Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design.
Jardine JG; Sok D; Julien JP; Briney B; Sarkar A; Liang CH; Scherer EA; Henry Dunand CJ; Adachi Y; Diwanji D; Hsueh J; Jones M; Kalyuzhniy O; Kubitz M; Spencer S; Pauthner M; Saye-Francisco KL; Sesterhenn F; Wilson PC; Galloway DM; Stanfield RL; Wilson IA; Burton DR; Schief WR
PLoS Pathog; 2016 Aug; 12(8):e1005815. PubMed ID: 27560183
[TBL] [Abstract][Full Text] [Related]
38. Long-Term and Low-Level Envelope C2V3 Stimulation by Highly Diverse Virus Isolates Leads to Frequent Development of Broad and Elite Antibody Neutralization in HIV-1-Infected Individuals.
Martin F; Marcelino JM; Palladino C; Bártolo I; Tracana S; Moranguinho I; Gonçalves P; Mateus R; Calado R; Borrego P; Leitner T; Clemente S; Taveira N
Microbiol Spectr; 2022 Dec; 10(6):e0163422. PubMed ID: 36445130
[TBL] [Abstract][Full Text] [Related]
39. Identification of variant HIV envelope proteins with enhanced affinities for precursors to anti-gp41 broadly neutralizing antibodies.
Zhu H; Mathew E; Connelly SM; Zuber J; Sullivan M; Piepenbrink MS; Kobie JJ; Dumont ME
PLoS One; 2019; 14(9):e0221550. PubMed ID: 31504041
[TBL] [Abstract][Full Text] [Related]
40. Glycans Function as Anchors for Antibodies and Help Drive HIV Broadly Neutralizing Antibody Development.
Andrabi R; Su CY; Liang CH; Shivatare SS; Briney B; Voss JE; Nawazi SK; Wu CY; Wong CH; Burton DR
Immunity; 2017 Sep; 47(3):524-537.e3. PubMed ID: 28916265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
